MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ocular Therapeutix Company Profile (NASDAQ:OCUL)

Consensus Ratings for Ocular Therapeutix (NASDAQ:OCUL) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.50 (625.34% upside)

Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)
Show:
DateFirmActionRatingPrice TargetActions
6/6/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Morgan StanleyReiterated RatingOverweight$17.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/10/2016RBC CapitalReiterated RatingOutperform$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2015BTIG ResearchReiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/5/2015NomuraInitiated CoverageBuy$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2015OppenheimerBoost Price TargetOutperform$42.00 -> $49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Ocular Therapeutix (NASDAQ:OCUL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116($0.43)($0.44)$458.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.47)($0.43)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.38)($0.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.33)($0.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2015Q115($0.39)($0.35)$0.30 million$0.43 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015Q4($0.38)($0.37)$0.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q3 14($0.55)($0.48)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Ocular Therapeutix (NASDAQ:OCUL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ocular Therapeutix (NASDAQ:OCUL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/9/2016Amarpreet SawhneyCEOBuy10,000$6.70$67,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Amarpreet SawhneyCEOBuy10,000$8.25$82,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015James FortuneCOOSell9,470$17.16$162,505.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Amarpreet SawhneyCEOBuy15,000$16.50$247,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Charles M WardenDirectorSell320,000$22.00$7,040,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Charles M WardenDirectorSell427,000$22.00$9,394,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Svlsf Iv, LlcMajor ShareholderSell1,119,000$22.00$24,618,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2014Amarpreet SawhneyCEOBuy76,922$13.00$999,986.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2014Svlsf Iv, LlcMajor ShareholderBuy715,380$13.00$9,299,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Ocular Therapeutix (NASDAQ:OCUL)
DateHeadline
06/23/16 03:36 PMOCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia -
06/20/16 05:27 PMQCR Holdings Inc. (NASDAQ:QCRH) Went Down -3.63%: Ocular Therapeutix, Inc. (NASDAQ:OCUL), Equifax Inc ... - KC Register
06/18/16 09:49 AMOcular Therapeutix Inc. (OCUL) is Trading Lower on Unusual Volume for June 16 - Equities.com
06/16/16 09:48 AMOcular Therapeutix Inc. (OCUL) is Trading Lower on Unusual Volume for June 14 - Equities.com
06/15/16 10:10 AMInvestigation for Investors in Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) Announced
06/10/16 08:33 AMOcular Therapeutix Inc. (OCUL) is Trading Higher on Unusual Volume for June 08 - Equities.com
06/09/16 08:35 AMOcular Therapeutix Inc. (OCUL) is Trading Lower on Unusual Volume for June 07 - Equities.com
06/08/16 06:01 PMOCULAR THERAPEUTIX INC. (NASDAQ:OCUL) Financial Condition Compared to S&P 500 - CML News
06/07/16 05:50 PMAnalysts Offer Insights on Healthcare Companies: Ocular Therapeutix Inc (NASDAQ: OCUL), Gilead Sciences ... - Markets.co
06/07/16 05:49 PMWhy Shareholders Mustn't Give Up On Ocular Therapeutix Inc. (NASDAQ: OCUL) - Scibility Media
06/07/16 08:19 AMHC Stocks in Drift: Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), Ocular Therapeutix Inc (NASDAQ:OCUL) - share market updates (press release)
06/07/16 08:19 AMEarnings Estimates Highlight: Carnival Corporation (NYSE:CCL), Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Beacon Chronicle
06/07/16 08:19 AMWhat Now For ProNAi Therapeutics Inc (NASDAQ:DNAI) And Ocular Therapeutix Inc (NASDAQ:OCUL)? - Market Exclusive
06/06/16 09:17 AMPremarket Runners: Ocular Therapeutix Inc(NASDAQ:OCUL), Array Biopharma Inc(NASDAQ:ARRY) - iStreetWire
06/06/16 08:31 AMStocks to Watch: Adamis Pharmaceuticals, Ocular Therapeutix, ProNAi Therapeutics -
06/06/16 07:35 AMWhy Ocular Therapeutix Is Sinking Despite Mixed Results -
06/06/16 07:30 AMOcular Therapeutix Inc Conference Call to Discuss the Results of Phase 3 Clinical Trial for DEXTENZAT scheduled for 8:30 am ET today -
06/02/16 03:25 PMOcular Therapeutix™ to Present at Two Upcoming Investor Conferences - [at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 2, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ...
06/02/16 03:20 PMOCULAR THERAPEUTIX, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/01/16 06:06 PMOcular Therapeutix, Inc. (NASDAQ:OCUL) Quarterly EPS Estimate At $-0.49 - Investor Newswire - Ocular Therapeutix, Inc. (NASDAQ:OCUL) Quarterly EPS Estimate At $-0.49Investor NewswireFirst Call stated that Ocular Therapeutix, Inc. (NASDAQ:OCUL) can touch $38.75 in coming one year. For the next quarter, the per-share earnings target is $-0.49 and for ongoing fiscal at $-1.86. EPS target for next year is $-2.40 versus the mean EPS of ...and more »
05/28/16 10:04 AMOcular Therapeutix, Inc. (NASDAQ:OCUL) One-Year Price Target At $38.75 - Investor Newswire - Ocular Therapeutix, Inc. (NASDAQ:OCUL) One-Year Price Target At $38.75Investor NewswireFirst Call has set a 52-week price target of $38.75 on Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock after completion of its survey. For the approaching quarter, EPS estimate is set at $-0.49 and for underway fiscal at $-1.86. This estimate for next ...and more »
05/27/16 11:12 AMHC Stocks To Observe: Iradimed (IRMD), Ocular Therapeutix (OCUL) - share market updates (press release) - share market updates (press release)HC Stocks To Observe: Iradimed (IRMD), Ocular Therapeutix (OCUL)share market updates (press release)Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) ended Wednesday session in green amid volatile trading. The shares closed up +0.29 points or 2.50% at $11.88 with 126,786.00 shares getting traded. Post opening the session at $11.72, the shares hit an ...
05/26/16 10:14 AMLatest Analyst Ratings For Ocular Therapeutix, Inc. (OCUL) - Share Trading News - Latest Analyst Ratings For Ocular Therapeutix, Inc. (OCUL)Share Trading News04/07/2016 – Ocular Therapeutix, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 48 price target on the stock. 02/17/2016 – Ocular Therapeutix, Inc. was upgraded to “overweight” by analysts at Morgan Stanley.Ocular Therapeutix Incorporated (NASDAQ:OCUL) Short Interest Decreased By 6.62%Wall Street Hints and Newsall 2 news articles »
05/19/16 12:04 PMOCULAR THERAPEUTIX, INC Financials -
05/10/16 05:27 PMEdited Transcript of OCUL earnings conference call or presentation 10-May-16 12:00pm GMT -
05/10/16 06:18 AMOcular Therapeutix™ Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - PDUFA target action date of July 24, 2016 for DEXTENZA™ NDA for the treatment of post-surgical ocular pain Second Phase 3 clinical trial for DEXTENZA for the treatment of allergic conjunctivitis fully ...
05/10/16 06:08 AMOcular Therapeutix reports 1Q loss -
05/10/16 06:07 AMQ1 2016 Ocular Therapeutix Inc Earnings Release - Before Market Open -
05/03/16 03:20 PMOcular Therapeutix™ to Report First Quarter 2016 Financial Results - [at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--May 3, 2016-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ...
04/27/16 03:27 PMOcular TherapeutixTM Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension - [at noodls] - First Phase 3 trial expected to commence in the third quarter of 2016 Trial design to evaluate OTX-TP using placebo as comparator; no timolol validation arm required BEDFORD, Mass.--(BUSINESS WIRE)--Apr. ...
04/08/16 03:58 PMETF’s with exposure to Ocular Therapeutix, Inc. : April 8, 2016 -
03/10/16 01:44 PMEdited Transcript of OCUL earnings conference call or presentation 10-Mar-16 1:00pm GMT -
03/10/16 07:00 AMOcular Therapeutix Inc Earnings Call scheduled for 8:00 am ET today -
03/10/16 06:15 AMOcular Therapeutix reports 4Q loss -
03/10/16 06:14 AMOCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E -
03/10/16 06:07 AMQ4 2015 Ocular Therapeutix Inc Earnings Release - Before Market Open -
03/10/16 06:00 AMOcular TherapeutixTM Reports Fourth Quarter and Full Year 2015 Financial Results - [Business Wire] - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the fourth quarter of 2015 and the twelve months ended December 31, 2015.
03/02/16 03:05 PMOcular Therapeutix™ to Report Fourth Quarter and Full Year 2015 Financial Results - [Business Wire] - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2015, on Thursday, March 10, 2016.
02/20/16 01:58 PMTrade-Ideas: Ocular Therapeutix (OCUL) Is Today's Weak On High Relative Volume Stock - See the FREE profile for OCUL NOW at Trade-Ideas More details on OCUL: Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for eye diseases and conditions using its proprietary hydrogel ...
02/18/16 07:00 AMOcular TherapeutixTM to Present at Two Upcoming Investor Conferences - [Business Wire] - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye,
02/17/16 01:32 PMOcular Therapeutix Incorporated (NASDAQ:OCUL) Shorted Shares Increased By 2.04% - fdanewsalert.com - Ocular Therapeutix Incorporated (NASDAQ:OCUL) Shorted Shares Increased By 2.04%fdanewsalert.comThe short interest to Ocular Therapeutix Incorporated's float is 14.74%. The stock is up 12.52% or $0.7 after the news, hitting $6.29 per share. About 144,322 shares traded hands. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 73.15% since July 10, ...Ocular Therapeutix™ Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma ...Business Wire (press release)Ocular Therapeutix (OCUL) Provides Phase 3 Clinical Development Plan for OTX-TPStreetInsider.comall 4 news articles »
02/17/16 01:32 PMOcular Therapeutix Inc (OCUL) is Upgraded by Morgan Stanley to Overweight - Los Angeles Mirror - Ocular Therapeutix Inc (OCUL) is Upgraded by Morgan Stanley to OverweightLos Angeles MirrorToday Ocular Therapeutix Inc (OCUL) was Upgraded by Morgan Stanley to ” Overweight”. Earlier the firm had a rating of “Equal-Weight ” on the company shares. Morgan Stanley advised their investors in a research report released on Feb 17, 2016. Ocular ...
02/17/16 01:32 PMOcular Therapeutix's stock rockets 45% premarket after upbeat trial outlook - MarketWatch - Ocular Therapeutix's stock rockets 45% premarket after upbeat trial outlookMarketWatchOcular Therapeutix Inc. NASDAQ: OCUL. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders. /marketstate/country/us.
02/17/16 01:32 PMOcular Therapeutix Inc (NASDAQ:OCUL)'s Company Shares Increased 10.41% After High Volatility - fdanewsalert.com - 24/7 Wall St.Ocular Therapeutix Inc (NASDAQ:OCUL)'s Company Shares Increased 10.41% After High Volatilityfdanewsalert.comThe shares of Ocular Therapeutix Inc (NASDAQ:OCUL) increased by 10.41% in the last 20 days and rose 11.59% in the past 5 trading sessions. Ocular Therapeutix Inc (NASDAQ:OCUL) shares opened at $5.66 in the last session and had intraday high of ...Ocular Therapeutix Inc. (OCUL) Is Up Sharply On OTX-TP NewsRTT NewsOcular Therapeutix Inc (OCUL) Rating Increased to Overweight at Morgan StanleyIntercooler FinancialOcular Therapeutix Skyrockets on Positive FDA Meeting24/7 Wall St.Benzinga -Baystreet.caall 10 news articles »
02/17/16 12:47 PMOcular Therapeutix Spikes 45% On Drug News; Morgan Stanley Upgraded Co. To Overweight -
02/17/16 11:15 AMOne Reason Why Ocular (OCUL) Stock is Advancing Today -
02/17/16 10:52 AMThis firm is now one of just two Mass. biotechs trading up this year -
02/17/16 08:20 AMOcular Therapeutix Skyrockets on Positive FDA Meeting -
02/17/16 07:19 AMOcular Therapeutix upgraded by Morgan Stanley -
02/16/16 03:07 PM4:07 pm Ocular Therapeutix announces Phase 3 clinical development plan for OTX-TP, a therapy for Glaucoma and Ocular Hypertension; expected to commence in 3Q16 -
About Ocular Therapeutix

Ocular Therapeutix logoOcular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company's product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company's lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug. The OTX-TP product candidate incorporates the prostaglandin analog travoprost as an active pharmaceutical ingredient in its punctum plug.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OCUL
  • CUSIP:
Key Metrics:
  • Previous Close: $5.17
  • 50 Day Moving Average: $9.07
  • 200 Day Moving Average: $9.00
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $128.04M
  • Current Quarter EPS Consensus Estimate: $-1.86 EPS
Additional Links:
Ocular Therapeutix (NASDAQ:OCUL) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha